In a report released today, Joon Lee from Truist Financial reiterated a Buy rating on Catalyst Pharma (CPRX – Research Report). The company’s ...

Eli Lilly just scored a major win with its Phase 3 BRAVE-AA-PEDS study. The trial confirmed baricitinib's effectiveness in ...

The stock's fall snapped a two-day winning streak.

Catalyst synthesis is the process of fabricating catalytic materials. It aims to optimize factors such as the catalyst activity, selectivity, stability and cost. Unlocking the potential of ...

This was the stock's second consecutive day of gains.

In the US, healthcare expenditures and costs have been increasing. According to the Centers for Medicare & Medicaid Services, ...

Shri Amit Agrawal highlighted the rapid expansion of the sector, emphasizing India’s growing role in research and innovation.

Funded by investors such as Flagship and General Catalyst, the AI startup claims its platform will help scientists speed up ...

Catalyst Pharmaceuticals' current stock price only assumes historical momentum for existing drug portfolio continues. See why ...

Recursion is currently generating limited revenue through partnerships with larger pharmaceutical leaders like Merck and ...

We recently compiled a list of the 10 Best UK Growth Stocks to Buy Now. In this article, we are going to take a look at where ...

Catalyst Pharmaceuticals' Firdapse delivers strong growth with a 37% CAGR. Click here to find out why CPRX stock is a Hold.